111732
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
2004 年至 2024 年药物诱发急性泛发性发疹性脓疱病（AGEP）的风险因素：基于 FAERS 的真实世界研究
Authors Que H, Zheng X, Li X, Wang W
Received 5 June 2025
Accepted for publication 4 October 2025
Published 28 October 2025 Volume 2025:18 Pages 2835—2845
DOI https://doi.org/10.2147/CCID.S544845
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Monica K. Li
Huafa Que,1,2 Xianglong Zheng,1,3 Xiaojian Li,1 Wanchun Wang1,3
1Clinical Medical College, Jiangxi University of Chinese Medicine, Nanchang, 330004, People’s Republic of China; 2Department of Traditional Chinese Surgery, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200030, People’s Republic of China; 3Department of Traditional Chinese Surgery, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, People’s Republic of China
Correspondence: Wanchun Wang, Department of Traditional Chinese Surgery, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, People’s Republic of China, Email 1449892135@qq.com Xiaojian Li, Clinical Medical College, Jiangxi University of Chinese Medicine, Nanchang, 330004, People’s Republic of China, Email 374095342@qq.com
Objective: Acute Generalized Exanthematous Pustulosis (AGEP) is a rare but potentially life-threatening cutaneous adverse drug reaction. Due to its poor clinical outcomes and unclear pathogenesis, this study aimed to systematically evaluate the drug-related risk factors for AGEP using data from the FDA Adverse Event Reporting System (FAERS).
Methods: This real-world, retrospective pharmacovigilance study analyzed all AGEP-related reports submitted to the FAERS database between Q1 2004 and Q4 2024. Disproportionality analysis was performed using reporting odds ratios (RORs), with Bonferroni-adjusted p-values to identify high-risk drugs. Drugs identified by univariate analysis were further evaluated through LASSO regression and multivariable logistic regression to determine risk factors associated with AGEP.
Results: A total of 6,880 AGEP cases were identified, with a predominance of female patients (54.5%) and a median age of 59 years. Disproportionality analysis revealed 148 drugs with a significant signal for AGEP, mainly including antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antivirals. LASSO and multivariate logistic regression identified 17 drugs as risk factors for AGEP, including ceftriaxone (OR = 49.87), pantoprazole (OR = 31.39), and hydroxychloroquine (OR = 28.38). The model showed moderate predictive accuracy with an AUC of 0.69.
Conclusion: This study identified multiple drug classes significantly associated with AGEP using FAERS-based adverse event data. The findings highlight a higher susceptibility in middle-aged and younger populations and underscore the importance of enhanced monitoring for high-risk medications. Given the inherent limitations of spontaneous reporting systems, further prospective studies are needed to confirm these associations and explore underlying mechanisms.
Keywords: AGEP, FAERS, pharmacovigilance, disproportionality analysis
1Clinical Medical College, Jiangxi University of Chinese Medicine, Nanchang, 330004, People’s Republic of China; 2Department of Traditional Chinese Surgery, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200030, People’s Republic of China; 3Department of Traditional Chinese Surgery, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, People’s Republic of China
Correspondence: Wanchun Wang, Department of Traditional Chinese Surgery, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, People’s Republic of China, Email 1449892135@qq.com Xiaojian Li, Clinical Medical College, Jiangxi University of Chinese Medicine, Nanchang, 330004, People’s Republic of China, Email 374095342@qq.com
Objective: Acute Generalized Exanthematous Pustulosis (AGEP) is a rare but potentially life-threatening cutaneous adverse drug reaction. Due to its poor clinical outcomes and unclear pathogenesis, this study aimed to systematically evaluate the drug-related risk factors for AGEP using data from the FDA Adverse Event Reporting System (FAERS).
Methods: This real-world, retrospective pharmacovigilance study analyzed all AGEP-related reports submitted to the FAERS database between Q1 2004 and Q4 2024. Disproportionality analysis was performed using reporting odds ratios (RORs), with Bonferroni-adjusted p-values to identify high-risk drugs. Drugs identified by univariate analysis were further evaluated through LASSO regression and multivariable logistic regression to determine risk factors associated with AGEP.
Results: A total of 6,880 AGEP cases were identified, with a predominance of female patients (54.5%) and a median age of 59 years. Disproportionality analysis revealed 148 drugs with a significant signal for AGEP, mainly including antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antivirals. LASSO and multivariate logistic regression identified 17 drugs as risk factors for AGEP, including ceftriaxone (OR = 49.87), pantoprazole (OR = 31.39), and hydroxychloroquine (OR = 28.38). The model showed moderate predictive accuracy with an AUC of 0.69.
Conclusion: This study identified multiple drug classes significantly associated with AGEP using FAERS-based adverse event data. The findings highlight a higher susceptibility in middle-aged and younger populations and underscore the importance of enhanced monitoring for high-risk medications. Given the inherent limitations of spontaneous reporting systems, further prospective studies are needed to confirm these associations and explore underlying mechanisms.
Keywords: AGEP, FAERS, pharmacovigilance, disproportionality analysis